Case Comprehensive Cancer Center: Myelodysplastic Syndromes trials

The registry lists 24 Myelodysplastic Syndromes studies with Case Comprehensive Cancer Center as lead sponsor. 1 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 4Phase 2 16Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodRecruitingNCT06904482Phase 2
• CPX-351 Therapy for MDS After Hypomethylating Agent FailureTerminatedNCT03957876Phase 2Results posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic SyndromeCompletedNCT01165996Phase 1/2Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• RAD001(Everolimus) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00809185Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00054327Phase 2Results posted
• CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDSActive, not recruitingNCT04668885Phase 2
• TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic AcidCompletedNCT03397173Phase 2
• Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
• Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
• Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
• Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow TransplantationCompletedNCT00281801
• Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative DisorderCompletedNCT00274820Phase 2
• Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
• Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesCompletedNCT00068523Not applicable
• Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 1
• Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDSCompletedNCT00053287Phase 2
• Non-Ablative Allo HSCT For Hematologic Malignancies or SAACompletedNCT00006379Phase 2
• Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT00005593Phase 1
• Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic ConditionsCompletedNCT00003336Phase 2
• Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic CancerCompletedNCT00003335Phase 2
• High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003116Phase 2